Larotrectinib Has Wide-Ranging Efficacy in Advanced Solid Tumors with NTRK Gene Fusion

Wayne Kuznar

August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO 2019 Highlights - Biomarkers

Chicago, IL—In 2018, larotrectinib (Vitrakvi) became the first drug to be approved by the FDA as a tumor-agnostic therapy based solely on the presence of a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation TRK fusion biomarker. Several analyses presented at ASCO 2019 confirm the wide-ranging efficacy of larotrectinib in pediatric and adult patients with advanced cancer and NTRK gene fusion cancer, as well as those whose tumor involves the central nervous system (CNS). [ Read More ]